Journal
CANCER CELL
Volume 21, Issue 1, Pages 66-81Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2011.11.024
Keywords
-
Categories
Funding
- NIH [CA125550, CA155370, CA151925, DK81576, CA163191, DK55001, 2T32DK007760-11, 5T32CA081156-08, 5T32HL007374-30]
- Champalimaud metastasis programme
- NRSA from NIH/NIDDK [5F32DK082119-02]
- United Negro College
- DoD [W81XWH-09-1-0008]
Ask authors/readers for more resources
The functional role of pericytes in cancer progression remains unknown. Clinical studies suggest that low numbers of vessel-associated pericytes correlated with a drop in overall survival of patients with invasive breast cancer. Using genetic mouse models or pharmacological inhibitors, pericyte depletion suppressed tumor growth but enhanced metastasis. Pericyte depletion was further associated with increased hypoxia, epithelial-to-mesenchymal transition (EMT), and Met receptor activation. Silencing of Twist or use of a Met inhibitor suppressed hypoxia and EMT/Met-driven metastasis. In addition, poor pericyte coverage coupled with high Met expression in cancer cells speculates the worst prognosis for patients with invasive breast cancer. Collectively, our study suggests that pericytes within the primary tumor microenvironment likely serve as important gatekeepers against cancer progression and metastasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available